What question did this study set out to answer?

To review the pharmacokinetic profile, therapeutic efficacy, and safety profile of mexiletine for the oral management of chronic and refractory ventricular arrhythmias.

December 1, 1986Clinical Progress in Electrophysiology and Pacing

Mexiletine: Its Role in the Management of Chronic Ventricular Arrhythmias

View Full Paper

Ask AI

Bookmark

Why the study?

Does mexiletine improve control of ventricular arrhythmias in patients with symptomatic and refractory ventricular arrhythmias?

Population

Patients with symptomatic and refractory ventricular arrhythmias

Design

Review

Follow-up

1 year

Authors

MSMagdi SamiSan Francisco General Hospital

Discussion

Member takes

Implication

Variable long-term control with mexiletine suggests limited durability; leaves open need for randomized trials in refractory ventricular arrhythmias.

Key Points

To review the pharmacokinetic profile, therapeutic efficacy, and safety profile of mexiletine for the oral management of chronic and refractory ventricular arrhythmias.
Evaluated oral dosing regimens (200–300 mg every 6–8 hours) and resulting steady-state plasma concentrations (0.5–2.5 µg/mL) in patients with symptomatic, refractory ventricular arrhythmias.
Assessed initial arrhythmia suppression and ongoing control at one year of follow-up, both as monotherapy and in combination with other antiarrhythmic drugs.
Mexiletine achieved an initial treatment success rate of 55% and a 1-year success rate of 33% in patients with refractory arrhythmias, consistent with broader published rates ranging from 52% to 84%.
The agent demonstrated minimal negative inotropic effects even in patients with congestive heart failure and did not alter serum digoxin levels.
Adverse reactions were primarily noncardiac, led by gastric intolerance and central nervous system effects, alongside a ~10% incidence of generally non-significant proarrhythmia.

Structured PICO

Does mexiletine improve control of ventricular arrhythmias in patients with symptomatic and refractory ventricular arrhythmias?

Population

Patients with symptomatic and refractory ventricular arrhythmias

Intervention

Mexiletine (oral or intravenous, typical oral dose 200-300 mg every 6-8 hours)

Outcome

Control of ventricular arrhythmiassurrogate

Mexiletine is an effective oral class IB antiarrhythmic for chronic ventricular arrhythmias, particularly useful in combination therapy, with a favorable safety profile regarding cardiac contractility but notable gastric and CNS side effects.

Cite This Study

Magdi Sami (1986) studied this question.

synapsesocial.com/papers/6a9465bb5cc4cfd2f72dda84 https://doi.org/10.1111/j.1540-8167.1986.tb01737.x

View Full Paper

Ask AI

Bookmark

Implication

Variable long-term control with mexiletine suggests limited durability; leaves open need for randomized trials in refractory ventricular arrhythmias.

Mexiletine: Its Role in the Management of Chronic Ventricular Arrhythmias

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Mexiletine: Its Role in the Management of Chronic Ventricular Arrhythmias

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider